Skip to content
Screener

SI-BONE, Inc. SIBN Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$56.0MBeat by $667.6K
EPS-$0.09Beat by $0.06
Revenue estimate$55.3M
EPS estimate-$0.15
Our accelerating growth and expanding profitability reinforces our conviction in the demand for our superior platform technologies and the significant runway ahead. This quarter's record physician engagement reflects our strategy to develop unique procedural solutions for patients with compromised bone and underscores the meaningful market need we are addressing. We are excited about the upcoming third breakthrough device launch in the fourth quarter, a substantially improved reimbursement backdrop, and an expanding commercial reach. Together, these tailwinds position us to expand adoption, broaden patient access, and enter our next phase of strong, sustainable multi-year revenue growth.
Laura Francis

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$55.3M
EPS estimate-$0.13

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$830.94M+30.9%
Enterprise value$840.35M+31.8%
P/S+0.6×

FAQ

When did SI-BONE, Inc. report Q2 2026 earnings?
SI-BONE, Inc. (SIBN) reported Q2 2026 earnings on August 3, 2026 after market close.
What were SI-BONE, Inc.'s Q2 2026 revenue and EPS?
SI-BONE, Inc. reported revenue of $56.0M and eps of $-0.09 for Q2 2026.
Did SI-BONE, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $55.3M by $667.6K. EPS beat the consensus estimate of $-0.15 by $0.06.
How did SI-BONE, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.2% from $48.6M a year earlier and eps grew 35.7% from $-0.14.
Where can I find SI-BONE, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001459839-26-000066) and the 10-Q periodic report (0001459839-26-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.